Pelabresib in Combination With Ruxolitinib for Myelofibrosis

[Manouche]

“To our knowledge, the MANIFEST trial in JAKi treatment-naïve patients is the first study with a rational combination of BETi pelabresib and ruxolitinib that showed clinically meaningful durable improvements in splenomegaly and symptoms, was associated with biomarker findings indicating potential disease modification, and demonstrated a generally favorable safety profile. This combination has the potential to improve the standard of care for treatment-naïve patients with myelofibrosis and warrants further investigation. A randomized, double-blind, phase III study (MANIFEST-2) compares safety and efficacy of pelabresib in combination with ruxolitinib with those of ruxolitinib monotherapy in JAKi treatment-naïve patients (ClinicalTrails.gov identifier: NCT04603495)”

ascopubs.org/doi/full/10.12...

CONCLUSIONThe rational combination of the BETi pelabresib and ruxolitinib in JAKi-naïve patients with myelofibrosis was well tolerated and showed durable improvements in spleen and symptom burden, with associated biomarker findings of potential disease-modifying activity.

[Wyebird]

I’m afraid a lot of that is above me but if read correctly the conclusion is extremely favourable for MF treatment.

Thanks for posting.

[DJK12]

This does look promising especially as side effects don't mention causing or exacerbating neuropathic pain which some of the other potential new treatments include. Thank you for posting this.